Suboxone Related Published Studies
Well-designed clinical trials related to Suboxone (Buprenorphine / Naloxone)
Buprenorphine/naloxone treatment in primary care is associated with decreased human immunodeficiency virus risk behaviors. [2008.07]
Long-term treatment with buprenorphine/naloxone in primary care: results at 2-5 years. [2008.03]
A randomized trial of effectiveness and cost-effectiveness of observed versus unobserved administration of buprenorphine-naloxone for heroin dependence. [2007.12]
A stepped care strategy using buprenorphine and methadone versus conventional methadone maintenance in heroin dependence: a randomized controlled trial. [2007.05]
Patient satisfaction with primary care office-based buprenorphine/naloxone treatment. [2007.02]
Effects associated with double-blind omission of buprenorphine/naloxone over a 98-h period. [2006.12]
Pharmacokinetics, bioavailability and opioid effects of liquid versus tablet buprenorphine. [2006.03.15]
Anesthesia-assisted vs buprenorphine- or clonidine-assisted heroin detoxification and naltrexone induction: a randomized trial. [2005.08.24]
A multi-center randomized trial of buprenorphine-naloxone versus clonidine for opioid detoxification: findings from the National Institute on Drug Abuse Clinical Trials Network. [2005.08]
The practice of office-based buprenorphine treatment of opioid dependence: is it associated with new patients entering into treatment? [2005.07]
A dose-effect study of repeated administration of buprenorphine/naloxone on performance in opioid-dependent volunteers. [2004.05.10]
Pharmacokinetics and subjective effects of sublingual buprenorphine, alone or in combination with naloxone: lack of dose proportionality. [2004]
Controlled trial of maintenance treatment of intravenous buprenorphine dependence. [2003.10]
Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. [2003.09.04]
Controlled, randomized trial in maintenance treatment of intravenous buprenorphine dependence with naltrexone, methadone or buprenorphine: a novel study. [2003.09]
Effects of buprenorphine/naloxone in opioid-dependent humans. [2001.03]
Efficacy of daily and alternate-day dosing regimens with the combination buprenorphine-naloxone tablet. [2000.02.01]
Naltrexone shortened opioid detoxification with buprenorphine. [1999.10.01]
Onset, magnitude and duration of opioid blockade produced by buprenorphine and naltrexone in humans. [1999.07]
Effects of buprenorphine and naloxone in morphine-stabilized opioid addicts. [1998.03.01]
Controlled opioid withdrawal evaluation during 72 h dose omission in buprenorphine-maintained patients. [1997.04.14]
Reduction of opiate withdrawal-like symptoms by cocaine abuse during methadone and buprenorphine maintenance. [1994.11]
[Risk evaluation of oxygen desaturation after buprenorphine or morphine administration during the early postoperative period] [1994]
Buprenorphine alone and in combination with naloxone in non-dependent humans. [1992.08]
Development of buprenorphine for the treatment of opioid dependence. [1992]
[Influence of intrathecal morphine and buprenorphine on EEG and their analgesic effect] [1990.04]
Naloxone suppresses buprenorphine stimulation of plasma prolactin. [1989.04]
Buprenorphine antagonism of ventilatory depression following fentanyl anaesthesia. [1988.08]
Influence of naloxone on the postoperative analgesic and respiratory effects of buprenorphine. [1988]
Well-designed clinical trials possibly related to Suboxone (Buprenorphine / Naloxone)
Opioid-induced mast cell activation and vascular responses is not mediated by mu-opioid receptors: an in vivo microdialysis study in human skin. [2004.02]
Inducing placebo respiratory depressant responses in humans via opioid receptors. [1999.02]
Postoperative analgesia with epidural bupivacaine and low-dose fentanyl--a comparison of two concentrations. [1998.08]
Three methods of opioid detoxification in a primary care setting. A randomized trial. [1997.10.01]
Effects of naltrexone on response to intravenous cocaine, hydromorphone and their combination in humans. [1996.11]
Other research related to Suboxone (Buprenorphine / Naloxone)
Serotonin syndrome triggered by a single dose of suboxone. [2008.09]
Use of buprenorphine for addiction treatment: perspectives of addiction specialists and general psychiatrists. [2008.08]
A case of heroin overdose reversed by sublingually administered buprenorphine/naloxone (Suboxone). [2008.07]
A retrospective evaluation of patients switched from buprenorphine (Subutex) to the buprenorphine/naloxone combination (Suboxone). [2008.06.17]
The implementation of buprenorphine/naloxone in college health practice. [2008.01]
Interaction between buprenorphine and atazanavir or atazanavir/ritonavir. [2007.12.01]
Sublingual buprenorphine/naloxone precipitated withdrawal in subjects maintained on 100mg of daily methadone. [2007.10.08]
Suboxone (buprenorphine/naloxone) toxicity in pediatric patients: a case report. [2007.09]
Buprenorphine maintenance: a new treatment for opioid dependence. [2007.07]
Methadone vs. buprenorphine/naloxone during early opioid substitution treatment: a naturalistic comparison of cognitive performance relative to healthy controls. [2007.06.12]
Using buprenorphine short-term taper to facilitate early treatment engagement. [2007.06]
Sublingual buprenorphine/naloxone precipitated withdrawal in subjects maintained on 100mg of daily methadone. [2007.05.19]
Abuse liability of buprenorphine-naloxone tablets in untreated IV drug users. [2007.04.17]
Primary care office-based buprenorphine treatment: comparison of heroin and prescription opioid dependent patients. [2007.04]
Using buprenorphine to facilitate entry into residential therapeutic community rehabilitation. [2007.03]
Abuse of buprenorphine in the United States: 2003-2005. [2007]
Case series on the safe use of buprenorphine/naloxone in individuals with acute hepatitis C infection and abnormal hepatic liver transaminases. [2007]
A Trial of Integrated Buprenorphine/Naloxone and HIV Clinical Care. [2006.12.15]
Interactions between buprenorphine and antiretrovirals. II. The protease inhibitors nelfinavir, lopinavir/ritonavir, and ritonavir. [2006.12.15]
Effects associated with double-blind omission of buprenorphine/naloxone over a 98-h period. [2006.09.30]
Effect of buprenorphine and antiretroviral agents on the QT interval in opioid-dependent patients. [2006.03]
Inpatient initiation of buprenorphine maintenance vs. detoxification: can retention of opioid-dependent patients in outpatient counseling be improved? [2006.01]
Buprenorphine retention in primary care. [2005.11]
Interaction of mu-opioid receptor agonists and antagonists with the analgesic effect of buprenorphine in mice. [2005.10]
Buprenorphine/naloxone reduces the reinforcing and subjective effects of heroin in heroin-dependent volunteers. [2005.10]
Pharmacokinetics, bioavailability and opioid effects of liquid versus tablet buprenorphine. [2005.09.03]
Sublingual buprenorphine is effective in the treatment of chronic pain syndrome. [2005.09]
Buprenorphine for office-based treatment of patients with opioid addiction. [2005.06]
Pharmacists' and technicians' perceptions and attitudes toward dispensing buprenorphine/ naloxone to patients with opioid dependence. [2005.01]
Buprenorphine and a CRF1 antagonist block the acquisition of opiate withdrawal-induced conditioned place aversion in rats. [2005.01]
Office-based buprenorphine treatment for opioid-dependent patients. [2004.11]
A pilot study of buprenorphine-naloxone combination tablet (Suboxone) in treatment of opioid dependence. [2004.09]
Consensus statement on office-based treatment of opioid dependence using buprenorphine. [2004.09]
Buprenorphine in the treatment of opiate dependence: its pharmacology and social context of use in the U.S. [2004.05]
Buprenorphine: a primer for emergency physicians. [2004.05]
Counseling buprenorphine patients: information and treatment approaches for counselors. [2004.05]
Relative bioavailability of different buprenorphine formulations under chronic dosing conditions. [2004.04.09]
Buprenorphine produces naltrexone reversible alterations of immune status. [2004.03]
Bringing buprenorphine-naloxone detoxification to community treatment providers: the NIDA Clinical Trials Network field experience. [2004]
Buprenorphine for office-based practice: consensus conference overview. [2004]
Pharmacokinetics of high-dose buprenorphine following single administration of sublingual tablet formulations in opioid naive healthy male volunteers under a naltrexone block. [2003.10.24]
Serious overdoses involving buprenorphine in Helsinki. [2003.09]
Relative efficacy of buprenorphine, nalbuphine and morphine in opioid-treated rhesus monkeys discriminating naltrexone. [2003.09]
Buprenorphine blocks epsilon- and micro-opioid receptor-mediated antinociception in the mouse. [2003.07]
Ultra-rapid opiate detoxification using deep sedation and prior oral buprenorphine preparation: long-term results. [2003.04.01]
Buprenorphine TDS: use in daily practice, benefits for patients. [2003.02]
Short-term buprenorphine maintenance: treatment outcome. [2003]
Self-administration of intravenous buprenorphine and the buprenorphine/naloxone combination by recently detoxified heroin abusers. [2002.11]
The role of spinal opioid receptors in antinociceptive effects produced by intrathecal administration of hydromorphone and buprenorphine in the rat. [2002.06]
Buprenorphine and addiction: challenges for the pharmacist. [2002.05]
Opioid dependence treatment, including buprenorphine/naloxone. [2002.02]
Blockade of hydromorphone effects by buprenorphine/naloxone and buprenorphine. [2002.01]
Buprenorphine for opiate addiction: potential economic impact. [2001.08.01]
Effect of perinatal buprenorphine exposure on development in the rat. [2001.08]
Thrice-weekly supervised dosing with the combination buprenorphine-naloxone tablet is preferred to daily supervised dosing by opioid-dependent humans. [2001.01.01]
Buprenorphine substitution ameliorates spontaneous withdrawal in fentanyl-dependent rat pups. [2001.01]
Buprenorphine and naloxone co-administration in opiate-dependent patients stabilized on sublingual buprenorphine. [2000.12.22]
Buprenorphine and naloxone for heroin dependence. [2000.12]
Influence of buprenorphine, butorphanol and nalbuphine on the initiation of intravenous cocaine self-administration in drug naive mice. [2000.12]
Effects of buprenorphine versus buprenorphine/naloxone tablets in non-dependent opioid abusers. [2000.03]
Buprenorphine and naloxone combinations: the effects of three dose ratios in morphine-stabilized, opiate-dependent volunteers. [1999.01]
Influence of oral buprenorphine, oral naltrexone or morphine on the effects of laparotomy in the rat. [1998.04]
Discriminative stimulus effects of l-alpha-acetylmethadol (LAAM), buprenorphine and methadone in morphine-treated rhesus monkeys. [1997.08]
Buprenorphine and naloxone interactions in methadone maintenance patients. [1997.06.01]
Kinetics of respiratory depression in rats induced by buprenorphine and its metabolite, norbuprenorphine. [1997.04]
Buprenorphine and naloxone interactions in opiate-dependent volunteers. [1996.07]
The analgesic drug buprenorphine inhibits osteoclastic bone resorption in vitro, but is proinflammatory in rat adjuvant arthritis. [1996.06]
|
